[go: up one dir, main page]

TNSN04022A1 - Compositions pharmaceutiques d'amlodipine et d'atorvastatine - Google Patents

Compositions pharmaceutiques d'amlodipine et d'atorvastatine

Info

Publication number
TNSN04022A1
TNSN04022A1 TNP2004000022A TNSN04022A TNSN04022A1 TN SN04022 A1 TNSN04022 A1 TN SN04022A1 TN P2004000022 A TNP2004000022 A TN P2004000022A TN SN04022 A TNSN04022 A TN SN04022A TN SN04022 A1 TNSN04022 A1 TN SN04022A1
Authority
TN
Tunisia
Prior art keywords
amlodipine
atorvastatin
compositions
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
TNP2004000022A
Other languages
English (en)
Inventor
Laman Alani
Sadath Ulla Khan
Thomas Michael Macneil
Nouman Abdul-Hussain Muhammad
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TNSN04022A1 publication Critical patent/TNSN04022A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

UNE COMPOSITION PHARMACEUTIQUE COMPRENANT DEUX CONSTITUANTS: (A) UN CONSTITUANT COMPRENANT DES GRANULES D'ATORVASTATINE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN SUPPORT COMPRENANT UN AGENT ALCALINISANT QUI ENGENDRE UN PH SUPERIEUR A 5 ; ET (B) UN SECOND CONSTITUANT COMPRENANT DE L'AMLODIPINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN SUPPORT; A L'EXCLUSION D'UN AGENT ALCALINISANT; QUI ENGENDRE UN PH SUPERIEUR A 5; DANS LAQUELLE LES DEUX CONSTITUANTS SONT COMBINES POUR FORMER UNE COMPOSITION FINALE POUR UNE FORME POSOLOGIQUE SOLIDE; EST DECRITE; AINSI QUE DES PROCEDES POUR LA PREPARATION DE TELLES COMPOSITIONS; DES KITS CONTENANT CES COMPOSITIONS; ET UNE METHODE DE TRAITEMENT DE L'ANGINE DE POITRINE; DE L'ATHEROSCLEROSE; DE L'HYPERTENSION ET DE L'HYPERLIPIDEMIE ET/OU HYPERCHOLESTEROLEMIE ASSOCIEES; ET DES SYMPTOMES DE RISQUE CARDIAQUE AU MOYEN D'UNE QUANTITE THERAPEUTIQUEMENT EFFICACE DE LA COMPOSITION PHARMACEUTIQUE.
TNP2004000022A 2001-07-31 2004-01-30 Compositions pharmaceutiques d'amlodipine et d'atorvastatine TNSN04022A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30913301P 2001-07-31 2001-07-31
PCT/IB2002/002988 WO2003011283A1 (fr) 2001-07-31 2002-07-29 Compositions pharmaceutiques d'amlodipine et d'atorvastatine

Publications (1)

Publication Number Publication Date
TNSN04022A1 true TNSN04022A1 (fr) 2006-06-01

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000022A TNSN04022A1 (fr) 2001-07-31 2004-01-30 Compositions pharmaceutiques d'amlodipine et d'atorvastatine

Country Status (46)

Country Link
US (2) US20030114497A1 (fr)
EP (2) EP1852116A1 (fr)
JP (3) JP4020863B2 (fr)
KR (2) KR20040032148A (fr)
CN (2) CN101185646A (fr)
AP (1) AP1745A (fr)
AR (1) AR034925A1 (fr)
AT (1) ATE385793T1 (fr)
AU (1) AU2002355680B2 (fr)
BR (1) BR0211548A (fr)
CA (1) CA2444554C (fr)
CO (1) CO5540287A2 (fr)
CR (1) CR7219A (fr)
CY (1) CY1107245T1 (fr)
DE (1) DE60225014T2 (fr)
DK (1) DK1411923T3 (fr)
DO (1) DOP2002000445A (fr)
EA (1) EA006998B1 (fr)
EC (1) ECSP044965A (fr)
ES (1) ES2298381T3 (fr)
GE (1) GEP20063926B (fr)
GT (1) GT200200158A (fr)
HN (1) HN2002000198A (fr)
HR (1) HRP20040067A2 (fr)
HU (1) HUP0401569A2 (fr)
IL (1) IL159440A0 (fr)
IS (1) IS7089A (fr)
MA (1) MA27052A1 (fr)
MX (1) MXPA04000270A (fr)
MY (1) MY137519A (fr)
NI (1) NI200200095A (fr)
NO (1) NO20040405L (fr)
NZ (1) NZ530247A (fr)
OA (1) OA13300A (fr)
PA (1) PA8551701A1 (fr)
PE (1) PE20030324A1 (fr)
PL (1) PL368519A1 (fr)
PT (1) PT1411923E (fr)
RS (1) RS5304A (fr)
SG (1) SG143982A1 (fr)
SV (1) SV2003001189A (fr)
TN (1) TNSN04022A1 (fr)
UA (1) UA79750C2 (fr)
UY (1) UY27402A1 (fr)
WO (1) WO2003011283A1 (fr)
ZA (1) ZA200400659B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
EP1771455B1 (fr) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Produits de degradation oxydante du calcium d'atorvastatine
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (fr) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
BRPI0607791A2 (pt) * 2005-03-15 2010-03-23 Lupin Ltd composiÇÕes farmacÊuticas de amlodipina e benazepril
CN101415425B (zh) 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
KR100793321B1 (ko) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 후각장애 치료 및 예방용 조성물
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
EP2070520A1 (fr) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Composition pharmaceutique comportant au moins un agent actif et un liant, qui gonfle dans un support acide
WO2009116061A2 (fr) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
EP2341773A4 (fr) * 2008-09-24 2012-03-07 Merck Sharp & Dohme Compositions pharmaceutiques d atorvastatine
WO2011152803A1 (fr) * 2010-06-03 2011-12-08 Mahmut Bilgic Formulation hydrosoluble stable
EP2749281B1 (fr) 2011-08-26 2018-03-28 Osaka University Agent prophylactique/thérapeutique pour les complications vasculaires du diabète
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US10350171B2 (en) * 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN109180701A (zh) * 2018-09-07 2019-01-11 中国药科大学 一种化合物2016a0c1药物组合物的共无定形物
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
JP7660352B2 (ja) * 2019-09-02 2025-04-11 日本ジェネリック株式会社 アトルバスタチンカルシウム水和物及びエゼチミブを含む錠剤
CN111689922B (zh) * 2020-07-17 2022-03-15 江西施美药业股份有限公司 一种苯磺酸左旋氨氯地平环合杂质的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
CA2150372C (fr) * 1993-01-19 2002-08-20 Nancy L. Mills Composition orale stable de ci-981 et procede de preparation
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69634054T2 (de) * 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
EA000514B1 (ru) * 1995-11-02 1999-10-28 Варнер-Ламберт Компани Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
JP2001514224A (ja) * 1997-08-29 2001-09-11 ファイザー・プロダクツ・インク アムロジピンとスタチン化合物を含む併用療法
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
WO1999026583A2 (fr) * 1997-11-25 1999-06-03 Warner-Lambert Company Inhibition de l'oxydation de lipoproteines
HK1043741A1 (zh) * 1999-04-23 2002-09-27 Preston Mason R. 氨氯地平和阿托发司他汀的协作效应
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
US6835742B2 (en) * 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release

Also Published As

Publication number Publication date
ATE385793T1 (de) 2008-03-15
PL368519A1 (en) 2005-04-04
JP4020863B2 (ja) 2007-12-12
PA8551701A1 (es) 2003-02-14
CO5540287A2 (es) 2005-07-29
JP2007314566A (ja) 2007-12-06
EP1411923B1 (fr) 2008-02-13
EP1852116A1 (fr) 2007-11-07
MY137519A (en) 2009-02-27
NI200200095A (es) 2004-06-07
AR034925A1 (es) 2004-03-24
ECSP044965A (es) 2004-03-23
EA200400028A1 (ru) 2004-08-26
NZ530247A (en) 2006-06-30
AP2004002963A0 (en) 2004-03-31
AP1745A (en) 2007-05-30
HN2002000198A (es) 2005-10-20
WO2003011283A1 (fr) 2003-02-13
MA27052A1 (fr) 2004-12-20
HUP0401569A2 (hu) 2004-12-28
UY27402A1 (es) 2003-02-28
US20050107446A1 (en) 2005-05-19
OA13300A (en) 2007-04-13
ZA200400659B (en) 2005-04-28
CA2444554A1 (fr) 2003-02-13
DE60225014T2 (de) 2008-06-12
KR20060054495A (ko) 2006-05-22
CA2444554C (fr) 2007-09-04
ES2298381T3 (es) 2008-05-16
GEP20063926B (en) 2006-09-25
CR7219A (es) 2004-03-24
NO20040405L (no) 2004-03-08
KR100674762B1 (ko) 2007-01-25
JP2007153908A (ja) 2007-06-21
GT200200158A (es) 2003-05-15
EP1411923A1 (fr) 2004-04-28
EA006998B1 (ru) 2006-06-30
UA79750C2 (en) 2007-07-25
SG143982A1 (en) 2008-07-29
PE20030324A1 (es) 2003-04-03
DK1411923T3 (da) 2009-01-05
HRP20040067A2 (en) 2005-02-28
SV2003001189A (es) 2003-03-18
RS5304A (sr) 2006-10-27
DOP2002000445A (es) 2003-01-31
IS7089A (is) 2003-12-22
CN1617717A (zh) 2005-05-18
US20030114497A1 (en) 2003-06-19
AU2002355680B2 (en) 2007-11-15
CN101185646A (zh) 2008-05-28
JP2005501051A (ja) 2005-01-13
IL159440A0 (en) 2004-06-01
BR0211548A (pt) 2004-07-13
KR20040032148A (ko) 2004-04-14
PT1411923E (pt) 2008-04-02
MXPA04000270A (es) 2004-05-04
CY1107245T1 (el) 2012-11-21
DE60225014D1 (de) 2008-03-27

Similar Documents

Publication Publication Date Title
TNSN04022A1 (fr) Compositions pharmaceutiques d'amlodipine et d'atorvastatine
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
TNSN98156A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procede pour leur preparation
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
TNSN98140A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98227A1 (fr) Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant.
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
EA200000718A1 (ru) Композиции целекоксиба
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
BE1002406A5 (fr) Compositions pharmaceutiques.
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97208A1 (fr) Prevention de la perte et restauration de la masse osseuse par certains agonistes des prostaglandines
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
FR2668064B1 (fr) Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
TR199802345T2 (xx) Siklooksijenaz-2-arac�l� hastal�klarda g�nde bir kez tatbikat i�in bile�imler.
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
TNSN03085A1 (fr) Composition parenterale reconstituable contenant un inhibiteur de cox-2
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.